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Targeted deletionare known to vary in antibody binding and sensitivity to neutralization. In
response to selective pressure, the virus may conceal important neutralizing determinants, such as the CD4
binding site on gp120, through steric hindrance or conformational masking. The 3D structure of gp120 shows
ﬁve loop structures that surround the CD4 binding site (CD4BS) and may restrict antibody access to the site.
We have generated gp120 mutants lacking each of these loops and characterized them with a panel of
monoclonal antibodies, including b12 and F105. A targeted deletion in the β20–β21 loop resulted in gp120
with enhanced binding of both monoclonals. Enhancement of b12 binding suggests reduced steric hindrance,
since the antibody is relatively insensitive to conformation. Enhanced binding of F105, which depends
strongly on the protein conformation, suggests that the mutation may allow gp120 to move more freely into
the liganded form. The same viral strategies that limit antibody binding may also inhibit antibody induction.
Modiﬁed forms of gp120, in which the CD4 binding site is more exposed and accessible to antibodies, could
provide novel immunogens for eliciting antibodies to this broadly shared neutralizing determinant.
Published by Elsevier Inc.IntroductionHumans can produce cross reactive neutralizing antibodies to HIV-1
in response to infection, as found in polyclonal sera (Berkower et al.,
1989; Stamatos et al.,1998; Binley et al., 2004, Li et al., 2007) and human
monoclonal antibodies such as b12, F105, and 2G12, speciﬁc for gp120
(Burton et al.,1994; Trkola et al.,1996;Wilkinson et al., 2005), as well as
monoclonals 2F5 and 4E10, speciﬁc for gp41 (Muster et al., 1993;
Cardoso et al., 2005). These antibodies target conserved epitopes on the
envelope glycoproteins gp120 and gp41 that are shared among diverse
HIV isolates (Pantophlet and Burton, 2006). Yet, immunization with
these glycoproteins has failed so far to elicit broadly neutralizing
antibodies (Mascola et al., 1996), and this difﬁculty is considered one of
the major obstacles to HIV vaccine development (McMichael, 2006).
Despite immunizing with gp120 as close as possible to the native form
on the virus, the resulting antibodies tend to be speciﬁc for unique
determinants on the immunizing strain, rather than conserved
determinants that could protect against a broad spectrum of strains
in circulation (Flynn et al., 2005). Under selective pressure, the virus
may have developed structures that partially conceal vital envelope
domains and protect the virus against broadly neutralizing antibodies.
The CD4 binding site (CD4BS) performs essential viral functions
during receptor binding and cell entry (Olshevsky et al., 1990), but it
also deﬁnes a neutralizing surface on gp120 which is a target ofer).
nc.immunity (Berkower et al., 1991; Thali et al., 1992; Wyatt et al., 1995).
Since these functions are shared among all HIV-1 isolates, the
sequences are relatively conserved, and antibodies speciﬁc for this
site can neutralize a broad spectrum of HIV-1 strains (Binley et al.,
2004; Pantophlet and Burton, 2006). The site occupies a surface
formed by the inner and outer domains of gp120, with a hydrophobic
pocket at its center (Kwong et al., 1998). However, it is surrounded by
loop structures that partially overlay the site and may restrict
antibody binding. By removing these loops, we could expose the site
for improved antibody binding.
In earlier studies, point mutations were created for more than
eighty residues in gp120, and each mutant was carefully analyzed for
positive or negative effects on antibody binding (Olshevsky et al.,1990;
Thali et al., 1992; Pantophlet et al., 2003). The mutants were useful for
mapping contact residues for the antibodies. However, the change of a
single amino acid may be too subtle to enhance antibody binding to a
sterically protected CD4BS (Pantophlet et al., 2003). Similarly, it may
not alter the protein sufﬁciently to favor the conformation that exposes
the CD4BS for antibody binding. In this paper, we made targeted
deletions that were large enough to expose the CD4BS or to overcome
conformational barriers to antibody binding.
Deletion of nine amino acids in the β20–β21 loop gave enhanced
antibody binding to the CD4BS, both for a monoclonal that depends
strongly on the protein conformation and for one that is relatively
insensitive to it. Molecular modeling suggests that deletion of this
loopmay improve antibody binding both by reducing steric hindrance
and by altering the protein conformation to expose the CD4BS. The
Table 1
Loops surrounding the CD4 binding site
Loop Amino acids deleted gp120 domain 2° structure
A 275–282 ENFTDNAK C2 Β10–β11
B 366–371 GGDPEI C3 β15-α3
C 424–432 INMWQKVGK C4 β20–β21
D 457–468 DGGNSTETETEI V5 £V5–β24
E 472–476 GGDMR C5 Exit loop
Table 2
Non-overlapping DNA primers were used to generate mutations by the QuickChange
method
Loop Primer pairs Restriction enzyme
A CTGTGAAATTTATCGATCTAATTACTATGTCTTC Cla I
TGCTAAATCGATAATAGTACAGCTAAATGAATC
B CCATCGATTGCTTAAAGATTATTGT Cla I
CCATCGATTGTAACGCACAGTTTTA
C GCCACATATTTGCTAGCTGTTTTATTCTGCATTGGAGTG Nhe I
GGCAGAAAGTAGGGCTAGCAATGTATGCCCC
D ACCTCCATCCCGGGTTAGTAGCAGCCCTG Xma I
GCCCCGGGGCTTCAGACCTGGAGGAGGAGATATG
E CTCCTCCCGGGCGGAAGATCTCAGTCTCAG Xma I
CGCCCGGGAGGAGGGGACAATTGGAGAAGTGAATTAT
GGCCCGGGGGACAATTGGAGAAGTG
PCR products were cut with the indicated restriction enzyme and ligated together,
creating a deletion.
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induction of antibodies to conserved neutralizing determinants.
Modiﬁed forms of gp120 with improved antibody binding to the
CD4BS could provide novel immunogens capable of eliciting anti-
bodies to this broadly shared neutralizing determinant.
Results
Based on the 3D structure of gp120, we identiﬁed ﬁve loop
structures that surround the CD4 binding site in the liganded
conformation and may protect it from antibodies (Table 1). Loops A,
B, C and E are located in the conserved regions C2, C3, C4 and C5,
respectively, while loop D is in variable region V5. As shown in Fig. 1
(left panel), loops A and C are located on the right and left margins of
the CD4 binding site in the bound conformation, while loops B and E
form the ﬂoor and back wall of the site. Loop B has important contact
residues for CD4 (Olshevsky et al., 1990) and for antibodies (Pantoph-
let et al., 2003; Li et al., 2007). Loop C contributes to the bridging sheet
that holds together the inner and outer domains in the liganded
conformation (Kwong et al., 1998; Wyatt et al., 1998). The space
between loops B and C forms a hydrophobic pocket for CD4 binding.
Loop A anchors an oligosaccharide side chain, and removing this
group enhances b12 binding moderately (Koch et al., 2003). For
antibodies that bind this conformation, one or more of the loops may
interfere with antibody binding through steric hindrance.
A second conformation of gp120 is the unliganded form, as found
on the virus prior to binding its receptor (Fig. 1, right panel). In this
structure, loops B and C are located directly in front of the CD4 binding
site, where they could interfere with antibody binding by covering up
the site. Normally, when gp120 binds its receptor, these loops move
out of the way to reveal the CD4 binding pocket. However, by
stabilizing the unbound conformation, the loops may prevent theFig.1. The structure of gp120 wasmodeled based on unliganded SIV and CD4-bound HIV IIIB.
C cover the CD4 binding site in the unliganded form (right panel) but migrate relative to thformation and exposure of the CD4 binding site, so antibodies cannot
bind. Because of the potential to affect antibody binding, we prepared
mutant gp120s that lacked each loop structure and tested them for
exposure of the CD4 binding site.
Loop deletions were generated in gp120 of either the IIIB or 89.6
background by the QuickChangemethod (Burke et al., 1998). Since this
method introduces a new restriction site at the site of the deletion, we
conﬁrmed the presence of a novel restriction site for each mutant
(Table 2 and Fig. 2, left panel). For example, digestion from the Sal I
restriction site at the 5′ end of the expression cassette to the Nhe I
restriction site at the loop C deletion, revealed a new restriction
fragment at 1.95 kb, as predicted. This was conﬁrmed by sequencing.
Similar analysis of the other deletion mutants showed progressively
larger restriction fragments for deletion mutants A through E. As
described previously, the gp120 mutants were expressed in baculo-
virus recombinants in tandemwith HBsAg (Berkower et al., 2004). The
HBsAg-gp120 hybrids assembled into gp120-rich virus-like particles,
and these were puriﬁed by sedimentation at high MW in sucrose
gradients These partially puriﬁed mutant forms of gp120 were
expressed at the expected MW, were antigenically pure, and were
used in comparable amounts to the wild type gp120, as shown by
western blot (Fig. 2, lower panel).
Each gp120 variant was characterized for binding to a panel of
monoclonal antibodies. Monoclonal 2G12 binds N-linked sugars (atLoops A (yellow), B (red), C (magenta), D (rose), and E (blue) are highlighted. Loops B and
e α1 helix (blue) and rotate to expose the CD4BS site for ligand binding (left panel).
Fig. 2. Expression of loop deleted forms of gp120. Upper left: Restriction digest of plasmid DNA coding for the loop mutants. Each mutant was cut from Sal I at the 5′end of the
expression cassette to the new restriction site at the deletion, resulting in progressively longer fragments for loops A through E. Lower panel:Western blot of each gp120mutant using
2G12 to detect gp120 expression. Right panel: 2G12 binding indicates equal ELISA plate coating for two wild type gp120s (IIIB and 89.6) and for loop B (on IIIB background) or loop C
(on 89.6 background) deletion mutants.
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binding site (Scanlan et al., 2002). Since its binding was generally
unaffected by point mutations in loops A, B, C and E (Pantophlet et al.,
2003), we used it to deﬁne conditions of equal ELISA plate coating for
variant and wild type gp120. For example, equal binding of 2G12 was
demonstrated for gp120 of the IIIB wild type and its loop B mutant, as
well as the 89.6 wild type and its loop C mutant (Fig. 2, right panel).Fig. 3. Antibody binding to gp120 variants. Monoclonal antibodies b12 (left panel), and F105
gp120s of the 89.6 type (wild type or loop C deletion). Under conditions of equal plate coatin
blocked antibody binding completely. Deletion of loop C increased b12 binding 3-fold, to eqSimilar results were obtained using polyclonal HIV immune globulin
(not shown). In all subsequent experiments, various gp120s were
tested under conditions of equal plate coating as demonstrated by
equal 2G12 binding.
We measured antibody binding to the CD4BS using two mono-
clonals, b12 and F105. Both are speciﬁc for the CD4 binding site, but
their footprints are different, so they could be affected differently by(right) were tested on two gp120s of IIIB type (wild type or loop B deletion) or on two
g, both monoclonals consistently bound wild type IIIB better than 89.6. Loop B deletion
ual IIIB, and it enhanced F105 binding by more than 10-fold.
Fig. 4. Antibody binding to AT-2 inactivated HIV-1 virions of the IIIB type or SHIV virions of the 89.6 type or control microvesicles. Monoclonals b12 and F105 gave nearly the identical
pattern as observed for virus-like particles of the same gp120 type.
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gp120 of the IIIB wild type 2.8 to 4-fold better than gp120 of the 89.6
type (Fig. 3, left panel). This effect was even more pronounced for
monoclonal F105 (Fig. 3, right panel), which bound IIIB 8 to 16-fold
better than 89.6. Nearly identical results were obtained when the
assay was repeated using AT-2 inactivated HIV-1 virions instead of
recombinant gp120 particles (Fig. 4). Monoclonal b12 consistently
bound IIIB virions better than 89.6 virions, and the effect was even
greater for F105, indicating that these differences are an intrinsic
property of gp120 and are not an artifact of recombinant gp120
particles. The CD4 binding site may be better exposed for antibody
binding in IIIB, which is T cell line adapted, than in 89.6, which is a
primary isolate. Strain 89.6 may limit antibody binding by partially
concealing this site.
As shown in Fig. 3, deletion of loop B completely abrogated binding
of both monoclonal antibodies to gp120 of the IIIB type. This result
agrees with earlier studies showing that loop B contains critical
contact residues for both antibodies, including Gly 366, Gly 367, AspFig. 5. Effect of additional loop deletions on antibody binding. Monoclonals b12 (left panel) an
E deletion, and markedly reduced binding to loop A or D deleted gp120.368, and Glu 370 (Pantophlet et al., 2003). X-ray crystallographic
results also show that monoclonal b12 and CD4 straddle this loop in
the liganded form of gp120 (Zwick et al., 2003; Wilkinson et al., 2005;
Zhou et al., 2007).
Deletion of loop C increased b12 binding, as measured by ELISA
peak OD, by amean of 2.6+/−0.37 fold in six experiments. The deletion
was made in the 89.6 background, and it increased b12 binding to
nearly the same level or equal to IIIB (peak OD between 80 and 100% of
the IIIB value). Binding was increased over the entire range of antibody
concentrations, from low level binding to saturation. The effect of the
loop C deletion on apparent afﬁnity is shown by comparing half
maximal binding of the loop C mutant with the concentration of wild
type 89.6 needed to reach the same OD. As shown, loop C deletion
shifted the b12 binding curve to the left by 300-fold relative to wild
type gp120.
For F105, the enhanced binding was even greater, as measured by
peak OD (Fig. 3, right). Deletion of loop C consistently enhanced F105
binding relative to 89.6 wild type by a mean of 7.1+/−2.0 fold in sixd F105 (right) showed enhanced binding to loop C deleted gp120, minimal effect of loop
Fig. 6. CD-Ig binding was measured for gp120 of the IIIB type and its loop B deletion (left panel) or 89.6 with deletion of loops A, C or D (right panel). Deletion of loop B reduced CD4-Ig
binding to the level of the HBsAg control. The other loop deletions had little or no effect on CD4-Ig binding.
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100-fold, and could not be estimated accurately because 89.6 wild
type never achieved half maximal binding of the loop C mutant. This
result is consistent with X-ray crystallography of b12 bound to gp120,
showing that essential contact residues are not located within loop C
(Zhou et al., 2007). The fact that antibody binding to 89.6 envelope
was restored by a deletion indicates that wild type 89.6 does not lack
contact residues for antibody binding. Whatever mechanism allowed
89.6 to evade these two neutralizing antibodies, it was reversed by the
deletion of just nine conserved amino acids in loop C.
Deletion of loops A or D resulted in mutant gp120s that failed to
bind either monoclonal, b12 or F105 (Fig. 5). The effect of the loop A
deletion was much greater than the generally modest effects
(including enhancement) of single amino acid substitutions in the
same loop, while loop D includes residues that were identiﬁed as
critical by the substitution method (Pantophlet et al., 2003). Deletion
of three amino acids at loop E (Asp-Met-Arg) had no effect on b12
binding but inhibited F105 completely, and both ﬁndings agree with
the effect of multiple Ala substitutions at the same site (Pantophlet
et al., 2003). The different effects of loop E modiﬁcation on these two
monoclonals may reﬂect their different binding footprints within the
CD4BS.Fig. 7. Surface charge density of 89.6 gp120 (middle panel), loop C deleted gp120 (right) and
an elevated hydrophobic center surrounded by aweakly basic rim. This ﬁts well into the hydr
and even better in the expanded pocket and more diffuse negative charge of the loop C delWe measured binding of each gp120 variant to a multimeric form
of CD4-Ig that could detect binding even at low afﬁnity (Arthos et al.,
2002). Deletion of loop B, on the IIIB background, gave complete loss of
CD4-Ig binding (Fig. 6, left panel), which was nearly as low as the
HBsAg control. Deletion of loops A, C, or D on the 89.6 background had
little or no effect on CD4-Ig binding (Fig. 6, right panel). Some loop
deletions, such as loop B, had negative effects on both antibody and
CD4 binding, while others, such as loops A and D, inhibited one but not
the other. Loop C enhanced antibody binding without affecting CD4,
even though both ligands bind within the same binding pocket on
gp120.
The CD4 bound form of wild type gp120 (strain 89.6) and the
loop C mutant were modeled based on the crystal structures of gp120
from HIV-1 IIIB and SIV (Kwong et al., 1998; Chen et al., 2005). Com-
putational analysis of surface charge distribution indicates that hydro-
phobic and electrostatic interactions are the driving force for the
binding between gp120 and its ligands. As shown for monoclonal b12
(Fig. 7, left panel), the gp120-binding sites on CD4, b12, and F105 are
mainly hydrophobic to slightly positive charged, while the binding
pocket on gp120 is hydrophobic to slightly negative charged (Fig. 7,
middle). Deletion at loop C exposes the CD4 binding pocket beyond
normal for the bound conformation and increases its hydrophobicitymonoclonal antibody b12 (left panel). The antibody, like CD4 and F105 (not shown), has
ophobic pocket and surrounding negative charge of gp120 in the liganded conformation,
etion.
335I. Berkower et al. / Virology 377 (2008) 330–338(Fig. 7, right panel), both of which will increase ligand binding. In
addition, deletion of loop C may destabilize the unliganded con-
formation by exposing a large hydrophobic cavity (radius 6.5 Å) that is
destabilized by water molecules trapped inside (not shown).
Discussion
Our results support the hypothesis that some strains of HIV can
evade antibodies by concealing important neutralizing determinants
on gp120. In the case of strain 89.6, we found restricted binding of
neutralizing monoclonal antibodies, both for AT-2 inactivated virions
and for virus-like particles that are rich in gp120. This was not caused
by variability in contact residues, since deletion of nine amino acids in
the β20–β21 loop of gp120 restored antibody binding to the level
observed in more susceptible strains, such as IIIB. Instead, antibody
binding was enhanced by removing local structures that may overlay
the CD4 binding site and conceal it. In addition, removing loop C may
allow gp120 to assume a conformation that exposes the CD4BS and
makes it more accessible for antibody binding.
The two monoclonals used in this study, b12 and F105, have
distinct footprints in the CD4BS and different sensitivity to gp120
conformation. Enhanced b12 binding suggests that the loop C deletion
reduced steric hindrance around the CD4 binding site, since b12
binding is relatively insensitive to the protein conformation (Kwong
et al., 2002). Molecular modeling agreed with this, showing that
deletion of loop C signiﬁcantly expanded the CD4 binding pocket in
the liganded conformation of gp120 and increased its accessibility to
neutralizing antibodies. Modeling also allowed us to examine
hydrophobic interactions within the CD4 binding pocket of native
gp120 and loop C deleted gp120. Fig. 8A shows the position of two
aromatic residues in or near loop C (magenta) in the liganded form of
native gp120. Trp 427 interacts with two residues on the α1 helix (His
104 and Trp 111), and Tyr 435 interacts mainly with Phe 382 of the
outer domain. In the loop C mutant, despite deletion of Trp 427,Fig. 8.Hydrophobic CD4 binding pocket of (A) wild type gp120 in the liganded conformation
and in (C) gp120 in complex with b12 (adapted from Zhou et al., 2007). Aromatic residues fr
mustard colors. (D) Loop C (magenta) is located directly between the CD4 binding pocket on
binding and coreceptor function (adapted from Rizzuto and Sodroski, 2000).Tyr 435 remains in contact with the same aromatic residue and
reconstitutes the CD4 binding pocket (Fig. 8B). Similarly, the crystal
structure of gp120 bound to b12 (Zhou et al., 2007) shows that Trp 427
is displaced from the CD4BS, while Tyr 435 remains in the binding
pocket (Fig. 8C). Since loop C residues are not close to the bound
antibody, it is not surprising that its deletion has no harmful effect on
b12 binding. In native gp120, loop C moves out of the way to expose
the CD4BS to the antibody. Once loop C is deleted, this is no longer
necessary.
Monoclonal F105 binding depends strongly on the conformation of
the CD4BS (Wilkinson et al., 2005), and its enhancement suggests that
loop C deletion can further enhance antibody binding through
conformational effects on gp120. Unliganded gp120, as found on
free virus, has a relatively closed CD4BS which is partially obstructed
by loop C (Chen et al., 2005). Receptor binding triggers a conforma-
tional change inwhich loop C migrates to form the bridging sheet and
exposes the CD4BS (Kwong et al., 1998). Loop C deletion could affect
the rate of formation and stability of the liganded conformation, with
its relatively exposed CD4 binding site. This may enhance F105
binding by increasing the representation of liganded forms among the
possible conformations of gp120.
Single amino acid substitutions for nearly every amino acid in
loop C have been studied for effects on antibody binding. Xiang et al.
(2002a), varied three amino acids of loop C simultaneously (Ile 423,
Asn 425, and Gly 431) and showed up to 25% enhancement of F105
and b12 binding. They attributed this to conformational effects on the
CD4BS. Pantophlet et al. (2003), made single Ala substitutions at ﬁve
loop C residues: one enhanced b12 binding (Val 430), while three
others were inhibitory (Met 426, Trp 427, and Lys 432). Zhou et al.
(2007), substituted Cys for two loop C residues (Gln 428 and Gly 431)
and stabilized the liganded form of gp120 for co-crystallization with
b12. In several cases, changes in loop C that favor the liganded form
were detected as enhanced antibody binding to the CD4BS. In earlier
work, while searching for the CD4BS, two groups studied gp120has at least seven aromatic groups. The pocket persists in (B) the loop C deletion mutant,
om loop C are shown in magenta, from the α1 helix in blue, and from the outer sheet in
its right and the coreceptor binding site (green) on its left, where it may coordinate CD4
Table 3
Neutralizing sensitivity vs. natural variation of loop C and ﬂanking sequences (from Leitner et al., 2007)
Loop C
HIV-1 Isolate B12 (ID90) F105 (ID50) Q I I N M W Q E V G K A M Reference
MN 0.4 10 – – – – – – – K – – – – – Moulard et al. (2002); Posner et al. (1993)
HXB2 1 0.4 – – – – – – – K – – – – – Zwick et al. (2001); Cavacini et al. (1995)
JR-FL 3.4 – – – – – – – – – – – – – – Moulard et al. (2002)
SF162 4 – – – – – R – – – – – – – – Moulard et al. (2002)
89.6 6.25 49 – – – – – – – K – – – – – Zwick et al. (2001); Baba et al. (2000)
JR-CSF 20 N20 – – – – – – – – – – – – – Zwick et al. (2001); Chomont et al. (2008)
BaL 23 20 – – – – – – – K – – R – – Moulard et al. (2002); Chomont et al. (2008)
SF2 25 6 – – – – – – – – – – – – – Moulard et al. (2002); Posner et al. (1993)
HIV-2 – – – – T – H K – – R N V
SIV – V V – D – Y T – S – K V
Occurrence,% clade B 99.5 92.4 79.6 98.8 76.6 99.5 99.8 74.9 100 99.5 96.1 100 97.3
Variability (Kabat) 3 5.4 6.3 5.1 7.8 2 2 13.4 1 2 3.1 1 3.1
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12 amino acids from the middle of loop C down to Pro 437, and
Cordonnier et al. (1989) deleted 9 upstream amino acids from Arg 419
to the middle of loop C. Both showed loss of binding to monomeric
CD4. Each of these deletions extended four or ﬁve amino acids beyond
the amino or carboxyl end of our loop C deletion, and this may explain
different effects on CD4 binding. Although human monoclonal
antibodies to the CD4BS were not available at that time, Lasky et al.
(1987) reported a murine monoclonal antibody, called 5C2E5, that
bound an epitope matching loop C and inhibited CD4 binding.
As shown by Kwong et al. (2002), each monoclonal used in this
study bound gp120 with high afﬁnity, reﬂecting similar free energy of
binding, but they arrived at this by different routes. F105 had to
overcome a very great entropy barrier (18 kcal/mol), while b12 had
much less entropy effect (5.9 kcal/mol), and monoclonal 2G12 had
none. The entropy barrier for F105 reﬂects its dependence on the
bound conformation. The virtual inability of 89.6 gp120 with loop C
present to bind F105, as compared to the mutant, suggests that loop C
may inﬂuence its ability to assume the open conformation. The N100-
fold enhanced afﬁnity of F105 for loop C deleted gp120 would
correspond to a reduction in binding energy of at least 3 kcal/mol.
Considerable further enhancement is possible, particularly since the
combination of two mutations with additive effects on free energy
would have multiplicative effects on binding afﬁnity. The most
promising double mutants would combine one that favors the
liganded conformation with another that improves antibody access
to the CD4BS, and loop C appears to do some of each.
Loop C is required for infectivity, as shown by the failure to infect
cells with pseudovirions bearing loop C deleted gp160 (H. Chen, R.
Vassell, K. Virnik and I. Berkower, unpublished observations).
Although it was incorporated into pseudovirions as well as wild
type gp160, the loop C mutant was unable to support infection, as
measured by luciferase expression (Connor et al., 1995). Since loop C
deleted gp120 binds CD4 normally, this result suggests that loop C
performs an essential viral function following receptor binding that
may affect cell entry or viral uncoating. As shown in Fig. 8D (based on
Rizzuto et al., 1998 and Rizzuto and Sodroski, 2000), loop C is located
directly between the CD4 and coreceptor binding sites, where it may
coordinate CD4 binding with activation of coreceptor binding.
Preliminary experiments with loop C deleted IIIB gp120 indicate that
loop C deletion prevents the induction by CD4 of determinants
recognized bymonoclonal 17b. The V3-C4 region of gp120, where loop
C is located, is known to be involved in coreceptor function (LaBranche
et al., 1999). Mutations in this region are associated with a CD4-
independent phenotype, and a mutation within loop C restored CD4
dependence. Thus, loop C is in a good position to mediate between
CD4 binding and activation of coreceptor binding.
Wehave analyzed thenatural variation of loop C amongeight clade B
viruses, as compared to their sensitivity to neutralization by mono-
clonals b12 and F105 (Table 3). Within clade B, there were very fewamino acid changes in loop C, except in residue 429, which could be
either Glu or Lys. None of these substitutions correlated with sensitivity
to neutralizing antibodies over a 60-fold range for b12 or over a 100-fold
range for F105. However, the variation in antibody binding to strains IIIB
and 89.6 does correlate with sensitivity to neutralization. For mono-
clonal b12, weaker binding of strain 89.6 correlated with a 6-fold lower
sensitivity to neutralization. Even weaker binding of monoclonal F105
correlated with 100-fold reduced sensitivity to neutralization by this
antibody. These differences were not due to the loop C sequence, which
is identical in these two strains. Instead, backbone residues of 89.6 may
allow loop C to cover the CD4BS, so the deletion exposes the site for
antibody binding and neutralization. Alternatively, the 89.6 backbone
may favor the unliganded conformation, and removal of loop C partially
reverses this effect.
The CD4BS is an important target of neutralizing antibodies, but
these are rarely induced by native gp120 vaccines. Monoclonal and
polyclonal antibodies speciﬁc for the site can neutralize a broad
spectrum of HIV-1 isolates (Binley et al., 2004). However, wild type
gp120s, which grew under strong selective pressure of neutralizing
antibodies,may conceal the CD4 binding site from antibodies in order to
protect the virus from neutralization. Similarly, many CD4BS antibodies
prefer the liganded conformation, but the virus keeps only a small
fraction of gp120molecules in this form, as shown by low basal levels of
coreceptor binding (Decker et al., 2005) and CD4 inducible epitopes
(Wyatt et al., 1995). To elicit these antibodies, it may be necessary to
immunize with forms of gp120 that spontaneously adopt the liganded
conformation. Unlike earlier efforts of this type (Xiang et al. 2002a; Dey
et al., 2007), which modiﬁed gp120 to bind b12 selectively, our new
constructs indicate ways to enhance binding of CD4BS antibodies more
generally. The same features that limit antibody binding may also
interferewith antibody induction by conventional gp120 vaccines. Loop
deletion mutants with enhanced antibody bindingmay be the ﬁrst step
toward reversing a viral strategy of escape from neutralizing antibodies
and enhancing the ability to elicit these antibodies through
immunization.
Materials and methods
Antibodies and antigens
Antibodies were obtained from the NIH AIDS Research and
Reference Reagent Program. They include: monoclonal 2G12 from Dr.
Hermann Katinger (Trkola et al., 1996), monoclonal IgG1 b12 from Dr.
Dennis Burton and Carlos Barbas (Burton et al.,1994),monoclonal F105
fromDr. Marshall Posner and Dr. Lisa Cavacini (Posner et al., 1993), and
polyclonal HIV immunoglobulin. Multivalent CD4-Ig was a kind gift
from Dr. James Arthos, NIH (Arthos et al., 2002). Aldrithiol-2 in-
activated HIV-1 virions of the IIIB strain or SHIV virions of the 89.6 type
were a kind gift of Drs. Larry Arthur and Jeffrey Lifson at the AIDS
Vaccine Program, NCI (Lifson et al., 2004).
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Plasmids coding for HIV gp120 of the IIIB and 89.6 strains (Collman
et al., 1992) were kindly provided by Dr. Dan Littman (New York
University, New York, N.Y.). The gp120 genes were cloned downstream
of the baculovirus polyhedrin promoter in a pfastbac vector (Luckow
et al., 1993) in tandemwith codon-optimized synthetic HBsAg and the
inﬂuenza hemagglutinin signal peptide, and V1V2 regions were
deleted as described previously (Berkower et al., 2004). To create
loop deletions, the pfastbac plasmids were mutagenized by the
QuickChange method (Burke et al., 1998), using non-overlapping
primer pairs shown in Table 2. When the ends of the PCR ampliﬁed
products were cut with restriction enzyme and ligated together, the
gap between primers created a deletion in gp120. The mutants were
screened for acquisition of a new restriction site at the site of the
deletion, and the gp120 deletions were conﬁrmed by DNA sequencing.
The pfastbac DNA was then transposed into bacmid DNA coding for
infectious baculovirus. For all loop deletions but one, themutationwas
made on the 89.6 background. Since loop B contained multiple critical
residues, we used the IIIB background, so it would start with a high
binding phenotype.
Baculovirus recombinants
Bacmids were transformed into Sf-9 cells (ATG Laboratories, Eden
Prairie, MN). After 3 to 4 days in culture, cell pellets were suspended in
PBS at 5×106/ml, sonicated and screened for protein expression by
western blot. Positive viruses were plaque puriﬁed, screened for
protein expression, and expanded to 200 ml of titered baculovirus.
Protein expression and puriﬁcation
Hi 5 cells were cultured overnight at 0.8×106 per ml and then
infected with titered stocks of baculovirus recombinants at a moi of 3
to 5:1. After 28 h on a shaker at 27 °C, the infected cells were harvested
by centrifugation at 1000 rpm for 10 min in a Sorvall RT6000
centrifuge. Preliminary experiments showed that 28 to 30 h gave the
greatest yield, and that most of the protein remained intracellular. The
cell pellet from 200 ml of culture were resuspended in 10 ml PBS and
stored frozen at −80 °C. The cells were thawed, diluted 1:1 with PBS in
0.5% CHAPS plus protease inhibitor cocktail (BD Pharmingen). After
30 min at 4 °C, they were sonicated for 40 s in a Vibra Cell sonicator
with an external probe, followed by centrifugation for 10 min at
2000 rpm in a TJ-6 desktop centrifuge to remove cell debris.
In these HBsAg-gp120 hybrids, HBsAg acts as a carrier protein that
assembles and incorporates gp120 into virus-like particles. Ten
milliliters of the supernatant was layered onto a discontinuous
sucrose gradient, consisting of layers of 10%, 20% and 40% sucrose,
and sedimented in a Beckman SW28 rotor for 2 1/3 h at 27,000 rpm.
Fractions of about 0.7 ml each were collected from the bottom of the
tube and assayed for gp120 content by ELISA using 2G12 as the
primary antibody and goat anti-human IgG conjugated to alkaline
phosphatase (MP Biomedicals, Aurora, OH), as the detecting reagent.
Peak fractions were pooled and diaﬁltered against PBS.
Antibody binding ELISA assays
Each puriﬁed gp120 was serially diluted on ELISA plates and tested
for 2G12 binding. Dilutions that gave approximately 1 OD in 20 min
were chosen for subsequent experiments. Equivalent amounts of each
variant gp120 were coated side by side on an ELISA plate overnight at
4 °C. The plates were blocked with 1% BSA, andmonoclonal antibodies
or CD4-Ig were serially diluted 3-fold, starting at a concentration of
3 μg/ml. After 2 h at 25 °C, the plates were washed, and goat anti-
human IgG conjugated alkaline phosphatase was added as second
antibody. After another 1 1/2 h at 25 °C, the plates were washed,phosphatase substrate was added, and OD410 measured in an ELISA
plate reader. For each gp120 variant, the OD readings for antibody
bindingwere normalized to a time point when peak 2G12 bindingwas
between 1.6 and 2 OD. Differences in apparent afﬁnities were
determined by comparing half maximal binding for each gp120
variant. The results must be interpreted carefully, since binding was
measured on the solid phase, not in solution, and the antigens are
multimeric virus-like particles, which tend to increase the apparent
afﬁnity.
Structure modeling and computational analysis
The CD4 bound and unliganded forms of gp120 for the 89.6 strain
were modeled based on the crystal structures for HIV and SIV gp120
(Kwong et al., 1998; Chen et al., 2005). Sequence alignment between
the templates of the crystal structures and strain 89.6 were carried out
by using HMAP (Tang et al., 2003) and then adjusted manually,
conserving the overall secondary structure and positioning the
residues known to be important in the family. Five out of seven S–S
bonds in SIV gp120 are conserved in the unliganded state of 89.6
gp120. The model was built using NEST in the Jackal package (http://
cmm.cit.nih.gov/∼xiang) (Xiang, 2006). The gp120 conformation of
loop mutants was modeled using the LOOPY program (Xiang et al.,
2002b). All models were subjected to energy minimization using the
TINKER minimization protocol (http://dasher.wustl.edu/tinker/)
under the CHARMM all-atom force ﬁeld (Mackerell et al., 1998).
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